CTOs on the Move


 
NOVOS develops science-based solutions to slow down human aging. NOVOS is a Public Benefit Corporation devoted to improving human longevity & health.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

ArrePath

ArrePath is a biotech company discovering and developing new and differentiated classes of anti-infectives to address antimicrobial resistance (AMR) through the application of state of the art technologies and novel strategies.

Socati

Socati is the most advanced producer of THC-free full spectrum hemp. Purpose built for CBD infused products at global manufacturing scale, we combine expertise in seed genetics, proprietary extraction techniques and the most efficient purification systems available today. By integrating the entire supply chain, Socati is your partner in delivering to one of the most lucrative new product categories in history - non-psychoactive cannabinoid infusion.

GluStitch

GluStitch, Inc. is a Delta, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MediGene

About MediGene: MediGene AG is a publicly quoted (Frankfurt: Prime Standard), German-American biotechnology company located in Martinsried, Germany and San Diego, USA. MediGene is the first German biotech company with a drug on the market. The company

Arcutis

Arcutis was founded in 2016 to address significant unmet needs in medical dermatology. The company is a clinical-stage biopharmaceutical company focused on developing and commercializing best-in-class products. Our strategy is to exploit recent innovations in inflammation and immunology to bring the best molecules to bear against validated physiologic targets known to treat dermatological diseases and disorders. Our management team has extensive expertise in the development and commercialization of medical dermatology products, having held key leadership roles at a number of leading dermatology companies and, collectively, has successfully developed more than 50 FDA-approved products. We believe that by leveraging our team`s unique experience and demonstrated expertise to identify, develop and commercialize best-in-class molecules against validated targets, we will be able to develop differentiated products in less time, at lower cost, and at substantially lower risk than other approaches. Arcutis` combination of vision, unmet medical need, experienced management and strategic approach has attracted support from leading investors in the life sciences sector.